Literature DB >> 23026621

Risk factors and survival impact of primary graft dysfunction after lung transplantation in a single institution.

M N Samano1, L M Fernandes, J C B Baranauskas, A T Correia, J E Afonso, R H O B Teixeira, M L Caramori, P M Pêgo-Fernandes, F B Jatene.   

Abstract

BACKGROUND: Lung transplantation has become a standard procedure for some end-stage lung diseases, but primary graft dysfunction (PGD) is an inherent problem that impacts early and late outcomes. The aim of this study was to define the incidence, risk factors, and impact of mechanical ventilation time on mortality rates among a retrospective cohort of lung transplantations performed in a single institution.
METHODS: We performed a retrospective study of 118 lung transplantations performed between January 2003 and July 2010. The most severe form of PGD (grade III) as defined at 48 and 72 hours was examined for risk factors by multivariable logistic regression models using donor, recipient, and transplant variables.
RESULTS: The overall incidence of PGD at 48 hours was 19.8%, and 15.4% at 72 hours. According multivariate analysis, risk factors associated with PGD were donor smoking history for 48 hours (adjusted odds ratio [OR], 4.83; 95% confidence interval [CI], 1.236-18.896; P = .022) and older donors for 72 hours (adjusted OR, 1.046; 95% CI, 0.997-1.098; P = .022). The operative mortality was 52.9% among patients with PGD versus 20.3% at 48 hours (P = .012). At 72 hours, the mortality rate was 58.3% versus 21.2% (P = .013). The 90-days mortality was also higher among patients with PGD. The mechanical ventilation time was longer in patients with PGD III at 48 hours namely, a mean time of 72 versus 24 hours (P = .001). When PGD was defined at 72 hours, the mean ventilation time was even longer, namely 151 versus 24 hours (P < .001). The mean overall survival for patients who developed PGD at 48 hours was 490.9 versus 1665.5 days for subjects without PGD (P = .001). Considering PGD only at 72 hours, the mean survival was 177.7 days for the PGD group and 1628.9 days for the other patients (P < .001).
CONCLUSION: PGD showed an important impacts on operative and 90-day mortality rates, mechanical ventilation time, and overall survival among lung transplant patients. PGD at 72 hours was a better predictor of lung transplant outcomes than at 48 hours. The use of donors with a smoking history or of advanced age were risk factors for the development of PGD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23026621     DOI: 10.1016/j.transproceed.2012.07.134

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  12 in total

1.  Multidisciplinary collaboration: the key to advancing lung transplantation outcomes.

Authors:  Archer Kilbourne Martin; Ashley Virginia Fritz; Harish Ramakrishna
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-04-29

2.  Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant.

Authors:  Mary K Porteous; Bonnie Ky; James N Kirkpatrick; Russell Shinohara; Joshua M Diamond; Rupal J Shah; James C Lee; Jason D Christie; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

Review 3.  Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation.

Authors:  Mary K Porteous; Joshua M Diamond; Jason D Christie
Journal:  Curr Opin Organ Transplant       Date:  2015-10       Impact factor: 2.640

Review 4.  Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis.

Authors:  Yao Liu; Yi Liu; Lili Su; Shu-juan Jiang
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 5.  Lung transplantation: overall approach regarding its major aspects.

Authors:  Priscila Cilene León Bueno de Camargo; Ricardo Henrique de Oliveira Braga Teixeira; Rafael Medeiros Carraro; Silvia Vidal Campos; José Eduardo Afonso Junior; André Nathan Costa; Lucas Matos Fernandes; Luis Gustavo Abdalla; Marcos Naoyuki Samano; Paulo Manuel Pêgo-Fernandes
Journal:  J Bras Pneumol       Date:  2015 Nov-Dec       Impact factor: 2.624

6.  Lung transplantation with extracorporeal membrane oxygenation as intraoperative support.

Authors:  Mariana Schettini-Soares; Pedro Henrique Cunha Leite; Ludhmila Abrahão Hajjar; André Nathan Costa; Paulo Manuel Pêgo-Fernandes; Marcos Naoyuki Samano
Journal:  J Bras Pneumol       Date:  2018 Sep-Oct       Impact factor: 2.624

7.  Extracorporeal Membrane Oxygenation and Lung Transplantation: Initial Experience at a Single Brazilian Center.

Authors:  Flávio Pola-Dos-Reis; Marcos Naoyuki Samano; Luis Gustavo Abdalla; Guilherme Vieira Soares de Carvalho; Lucas Matos Fernandes; Oswaldo Gomes-Júnior; Rafael Medeiros Carraro; Priscila Cilene Leon Bueno de Camargo; Ricardo Henrique Oliveira Braga Teixeira; José Eduardo Afonso-Júnior; Paulo Manoel Pêgo-Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2020-04-30       Impact factor: 2.365

8.  Using machine learning to estimate survival curves for patients receiving an increased risk for disease transmission heart, liver, or lung versus waiting for a standard organ.

Authors:  Ethan Mark; David Goldsman; Pinar Keskinocak; Joel Sokol
Journal:  Transpl Infect Dis       Date:  2019-10-09

Review 9.  Review 2: Primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets.

Authors:  Zhaosheng Jin; Ka Chun Suen; Zhiping Wang; Daqing Ma
Journal:  J Anesth       Date:  2020-07-20       Impact factor: 2.078

10.  Incidence of primary graft dysfunction is higher according to the new ISHLT 2016 guidelines and correlates with clinical and molecular risk factors.

Authors:  Daoud Daoud; Lourdes Chacon Alberty; Qi Wei; Camila Hochman Mendez; Muhammad Hassan Masood Virk; Jonathan Mase; Peter Jindra; Matthew Cusick; Hyewon Choi; Natalie Debolske; Luiz C Sampaio; Doris A Taylor; Gabriel Loor
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.